Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C19H18N2O3 and a molecular weight of approximately 322.36 g/mol[1][4][8]. It features an indolequinone core structure substituted with a hydroxymethyl group, a methyl group, and a methylaziridine moiety. The compound is listed as experimental in drug databases and has not been approved for any therapeutic use[2][4]. There are no reported clinical trials or approved indications for this molecule. Its mechanism of action is not explicitly described in public sources; however, its structural similarity to indolequinones suggests potential activity as an alkylating agent or redox-active cytotoxin (as seen in related compounds), but this remains speculative.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(hydroxymethyl)-1-methyl-5-(2-methylaziridin-1-yl)-2-phenyl-1H-indole-4,7-dione.